Bausch + Lomb Corporation Stock Price, News & Analysis

Bausch + Lomb (NYSE/TSX: BLCO) has announced that its innovative recycling programs, ONE by ONE and Biotrue Eye Care, have successfully collected over 58 million units (approximately 356,723 pounds) of used contact lenses and related materials since their inception. This effort, in collaboration with TerraCycle, helps reduce environmental pollution caused by non-biodegradable plastics in the U.S. The ONE by ONE program has been active since November 2016, while the Biotrue program began in April 2021. These initiatives highlight Bausch + Lomb's commitment to sustainability.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) will participate in the 5th Annual Evercore ISI HealthCONx Conference on November 30, 2022, at 9:40 a.m. ET. The event will feature CEO Joseph C. Papa and CFO Sam Eldessouky. A webcast of the presentation will be available on the company's Investor Relations page.

Founded in 1853, Bausch + Lomb is a global leader in eye health, offering over 400 products, including contact lenses and ophthalmic pharmaceuticals. The company is headquartered in Vaughan, Ontario, with a significant global presence.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) reported third-quarter 2022 revenues of $942 million, a 1% decline year-over-year, impacted by $55 million in foreign exchange losses. Adjusted EBITDA was $187 million, down from $207 million in 2021. The net loss attributable to the company was $18 million, compared to a net income of $60 million the previous year. Despite challenges, organic revenue grew 5%, driven by strong performance in all segments. The company revised its full-year 2022 guidance due to currency headwinds, with revised revenues expected between $3.70 billion and $3.75 billion.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched Project Watson, a new line of health care products for dogs in the U.S., aimed at enhancing their eye, ear, and overall wellbeing. Developed in collaboration with veterinarians, products include eye wash, eyelid wipes, ear wash, ear wipes, and health supplements targeting eye health and general health. The rollout begins in November 2022 at major retailers like Chewy and Walmart, contributing to Bausch + Lomb's longstanding commitment to pet care and addressing unmet health needs in pets.

Bausch + Lomb Corporation (BLCO) announced its participation in the American Academy of Optometry meeting from Oct. 26-29, 2022, in San Diego. The company will present four scientific posters highlighting its Biotrue Hydration Plus Multi-Purpose Solution, which offers enhanced moisture for contact lens wearers. CEO Joseph C. Papa emphasized the solution's benefits for eye care professionals and patients. Additionally, Bausch + Lomb will sponsor nine educational events focusing on various eye health topics, including dry eye disease and the latest clinical data.

Bausch + Lomb (NYSE/TSX: BLCO) will announce its third-quarter 2022 financial results on November 2, 2022, at 8:00 a.m. ET. A conference call and live webcast will follow, providing insights and updates on the company's performance. Interested parties can access the webcast on the company's website. Bausch + Lomb, a global leader in eye health with over 400 products, continues to focus on enhancing vision care and maintaining a strong market presence in nearly 100 countries.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) has launched an enhanced version of its Ocuvite Adult 50+ eye vitamin, now featuring 30 micrograms of vitamin D. This antioxidant aims to support healthy cell function and protect eye health, especially as aging can weaken the eyes’ natural defenses against daily stressors like screens and sunlight. The new formulation will replace the existing Ocuvite Adult 50+ and will be available in stores from October 2022 at a retail price of $12.85 for a 50-count bottle.

Bausch + Lomb Corporation (NYSE/TSX: BLCO) announces participation at the World Cornea Congress VIII on September 28-29, 2022, in Chicago. Key presentations include one podium and two poster presentations showcasing pivotal findings from Phase 3 trials of the investigational treatment NOV03 (perfluorohexyloctane) and data from its ARMOR surveillance study, which monitors antibiotic resistance among ocular pathogens. The FDA has recently accepted Bausch + Lomb's New Drug Application for NOV03, indicating progress in their clinical development program.